

PERSONAL INFORMATION

Enrique Gonzalez Billalabeitia

WORK EXPERIENCE

March 2020–Present

Head of Ambulatory Care

Hospital Universitario 12 de Octubre. Madrid (Spain)

Medical Oncologist.

June 2015–Present

Associate Professor

Universidad Catolica San Antonio de Murcia (Spain)

Coordinator of Oncology and Palliative Medicine

July 2003–February 2020

Staff

Hospital Universitario Morales Meseguer (Spain)

Medical oncologist

July 2003–Present

Assistant Professor.

Universidad de Murcia (Spain)

Department of Medicine

February 2013–September 2013

Associate Professor

Universidad de Murcia (Spain)

Biochemistry and molecular biology

EDUCATION AND TRAINING

October 2016–March 2017

Invited Researcher

Institute of Cancer Research-UK (United Kingdom)

Circulating tumor DNA. Prostate cancer

September 1992–June 1998

Medical Degree

Universidad de Navarra (Spain)

Medical Degree (M.D.)

May 1999–June 2003

Medical Oncology Specialist

Hospital 12 de Octubre. Madrid (Spain)

Medical Oncologist

April 2001–November 2006

PhD in Medicine

Universidad Complutense de Madrid (Spain)

July 2006–December 2008

Postgraduate studies in Statistics and Health Science

Universidad Autónoma de Barcelona (Spain)

September 2010–August 2012

Post-doctoral fellowship in genetics

Harvard University (Spain)

Pandolfi Laboratory. Prostate cancer animal models and translation.

ADDITIONAL INFORMATION

Expertise Medical oncology. Urological tumors. Molecular biology

- Publications**
- 1: Conteduca V, Wetterskog D, Scarpi E, Romanel A, Gurioli G, Jayaram A, Lolli C, Tandefelt DG, Schepisi G, Casadei C, Wingate A, Matteucci F, Paganelli G, Gonzalez-Billalabeitia E, Demichelis F, De Giorgi U, Attard G. Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. *Br J Cancer*. 2020 Jul 16. doi: 10.1038/s41416-020-0969-5. Epub ahead of print. PMID: 32669676.
 - 2: Khalaf DJ, Aragón IM, Annala M, Lozano R, Taavitsainen S, Lorente D, Finch DL, Romero-Laorden N, Vergidis J, Cendón Y, Oja C, Pacheco MI, Zulfiqar M; PROREPAIR-B investigators, Gleave ME, Wyatt AW, Olmos D, Chi KN, Castro E. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. *Ann Oncol*. 2020 Sep;31(9):1186-1197. doi: 10.1016/j.annonc.2020.06.006. Epub 2020 Jun 20. PMID: 32574722.
 - 3: González-Del-Alba A, Arranz JÁ, Bellmunt J, Maroto JP, Fernández-Calvo O, Valderrama BP, González-Billalabeitia E, Méndez-Vidal MJ, Cassinello J, Romero-Laorden N, Climent MÁ, Puente J, Peláez I, Lázaro-Quintela M, Gallardo E, Suárez C. Latest progress in molecular biology and treatment in genitourinary tumours. *Clin Transl Oncol*. 2020 May 21. doi: 10.1007/s12094-020-02373-z. Epub ahead of print. PMID: 32440915.
 - 4: Tran B, Ruiz-Morales JM, Gonzalez-Billalabeitia E, Patrikidou A, Amir E, Seidel C, Bokemeyer C, Fankhauser C, Hermanns T, Romyantsev A, Tryakin A, Brito M, Fléchon A, Kwan EM, Cheng T, Castellano D, Garcia Del Muro X, Hamid AA, Ottaviano M, Palmieri G, Kitson R, Reid A, Heng DY, Bedard PL. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3). *Cancer Med*. 2020 Jan;9(1):116-124. doi: 10.1002/cam4.2674. Epub 2019 Nov 12. PMID: 31715650; PMCID: PMC6943085.
 - 5: Conteduca V, Castro E, Wetterskog D, Scarpi E, Jayaram A, Romero-Laorden N, Olmos D, Gurioli G, Lolli C, Sáez MI, Puente J, Schepisi G, Salvi S, Wingate A, Medina A, Querol-Niñerola R, Marin-Aguilera M, Arranz JA, Fornarini G, Basso U, Mellado B, Gonzalez-Billalabeitia E, Attard G, De Giorgi U. Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. *Eur J Cancer*. 2019 Jul;116:158-168. doi: 10.1016/j.ejca.2019.05.007. Epub 2019 Jun 11. PMID: 31200322.
 - 6: Aparicio J, Sánchez-Muñoz A, Ochendusko S, Gumà J, Fernández-Aramburo A, García Del Muro X, Quiroga V, Sastre J, Alonso-Gordoa T, Sagastibelza N, Maroto P, Gómez de Liaño A, Vázquez S, Diz P, Durán I, Domenech M, Pinto A, Hernández A, González-Billalabeitia E, Terrasa J. Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group. *J Urol*. 2019 Oct;202(4):742-747. doi: 10.1097/JU.000000000000366. Epub 2019 Sep 6. PMID: 31163007.
 - 7: Luengo-Gil G, García-Martínez E, Chaves-Benito A, Conesa-Zamora P, Navarro-Manzano E, González-Billalabeitia E, García-Garre E, Martínez-Carrasco A, Vicente V, Ayala de la Peña F. Clinical and biological impact of miR-18a expression in breast cancer after neoadjuvant chemotherapy. *Cell Oncol (Dordr)*. 2019 Oct;42(5):627-644. doi: 10.1007/s13402-019-00450-2. Epub 2019 May 21. PMID: 31115881.
 - 8: Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin-Aguilera M, Lolli C, Schepisi G, Maugeri A, Wingate A, Farolfi A, Casadio V, Medina A, Puente J, Vidal MJM, Morales-Barrera R, Villa-Guzmán JC, Hernando S, Rodríguez-Vida A, González-Del-Alba A, Mellado B, Gonzalez-Billalabeitia E, Olmos D, Attard G, De Giorgi U. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. *Eur Urol*. 2019 Mar;75(3):368-373. doi: 10.1016/j.eururo.2018.09.049. Epub 2018 Oct 26. PMID: 30773204; PMCID: PMC6377278.
 - 9: Park MK, Yao Y, Xia W, Setijono SR, Kim JH, Vila IK, Chiu HH, Wu Y, Billalabeitia EG, Lee MG, Kalb RG, Hung MC, Pandolfi PP, Song SJ, Song MS. PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression. *Nat Commun*. 2019 Feb 7;10(1):636. doi: 10.1038/s41467-019-08481-x. PMID: 30733438; PMCID: PMC6367354.
 - 10: Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D,

Saez MI, Morales-Barrera R, Gonzalez-Billalabeitia E, Cendón Y, García-Carbonero I, Borrega P, Mendez Vidal MJ, Montesa A, Nombela P, Fernández-Parra E, Gonzalez Del Alba A, Villa-Guzmán JC, Ibáñez K, Rodríguez-Vida A, Magraner-Pardo L, Perez-Valderrama B, Vallespín E, Gallardo E, Vazquez S, Pritchard CC, Lapunzina P, Olmos D. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. *J Clin Oncol*. 2019 Feb 20;37(6):490-503. doi: 10.1200/JCO.18.00358. Epub 2019 Jan 9. PMID: 30625039.

11: González-Billalabeitia E, Conteduca V, Wetterskog D, Jayaram A, Attard G. Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test. *Prostate Cancer Prostatic Dis*. 2019 May;22(2):195-205. doi: 10.1038/s41391-018-0098-x. Epub 2018 Nov 9. PMID: 30413805; PMCID: PMC6398580.

12: Rosino A, Ballester I, Tudela J, González-Billalabeitia E. Quimioterapia en el cáncer de próstata resistente a la castración metastásico [Chemotherapy in metastatic castration resistant prostate cancer.]. *Arch Esp Urol*. 2018 Sep;71(8):676-684. Spanish. PMID: 30319127.

13: Paumard-Hernández B, Calvete O, Inglada Pérez L, Tejero H, Al-Shahrour F, Pita G, Barroso A, Carlos Triviño J, Urioste M, Valverde C, González Billalabeitia E, Quiroga V, Francisco Rodríguez Moreno J, Fernández Aramburo A, López C, Maroto P, Sastre J, José Juan Fita M, Duran I, Lorenzo-Lorenzo I, Iranzo P, García Del Muro X, Ros S, Zambrana F, María Autran A, Benítez J. Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer. *Int J Cancer*. 2018 Oct 15;143(8):1954-1962. doi: 10.1002/ijc.31604. Epub 2018 Aug 9. PMID: 29761480.

14: Luengo-Gil G, Gonzalez-Billalabeitia E, Perez-Henarejos SA, Navarro Manzano E, Chaves-Benito A, Garcia-Martinez E, Garcia-Garre E, Vicente V, Ayala de la Peña F. Angiogenic role of miR-20a in breast cancer. *PLoS One*. 2018 Apr 4;13(4):e0194638. doi: 10.1371/journal.pone.0194638. PMID: 29617404; PMCID: PMC5884522.

15: Aparicio J, Sánchez-Muñoz A, Gumà J, Domenech M, Meana JA, García-Sánchez J, Bastús R, Gironés R, González-Billalabeitia E, Sagastibelza N, Ochendusko S, Sánchez A, Terrasa J, Germà-Lluch JR, García Del Muro X; on behalf of the Spanish Germ Cell Cancer Group. A Risk-Adapted Approach to Patients with Stage I Seminoma according to the Status of Rete Testis: The Fourth Spanish Germ Cell Cancer Group Study. *Oncology*. 2018;95(1):8-12. doi: 10.1159/000487438. Epub 2018 Mar 26. PMID: 29587278.

16: García Garre E, Luengo Gil G, Montoro García S, Gonzalez Billalabeitia E, Zafra Poves M, García Martínez E, Roldán Schilling V, Navarro Manzano E, Ivars Rubio A, Lip GYH, Ayala de la Peña F. Circulating small-sized endothelial microparticles as predictors of clinical outcome after chemotherapy for breast cancer: an exploratory analysis. *Breast Cancer Res Treat*. 2018 May;169(1):83-92. doi: 10.1007/s10549-017-4656-z. Epub 2018 Jan 16. PMID: 29340882.

17: Chen M, Zhang J, Sampieri K, Clohessy JG, Mendez L, Gonzalez-Billalabeitia E, Liu XS, Lee YR, Fung J, Katon JM, Menon AV, Webster KA, Ng C, Palumbieri MD, DiIombi MS, Breitkopf SB, Teruya-Feldstein J, Signoretti S, Bronson RT, Asara JM, Castillo-Martin M, Cordon-Cardo C, Pandolfi PP. An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. *Nat Genet*. 2018 Feb;50(2):206-218. doi: 10.1038/s41588-017-0027-2. Epub 2018 Jan 15. PMID: 29335545; PMCID: PMC6714980.

18: González-Billalabeitia E, Sepúlveda JM, Maroto P, Aparicio J, Arranz JA, Esteban E, Gironés R, López-Brea M, Mendez-Vidal MJ, Pinto A, Sastre J, de Prado DS, Terrasa J, Vázquez S, Powles T, Beyer J, Castellano D, Del Muro XG; Spanish Germ Cell Cancer Group and the Spanish Oncology Genitourinary Group. Consensus Recommendations from the Spanish Germ Cell Cancer Group on the Use of High-dose Chemotherapy in Germ Cell Cancer. *Eur Urol Focus*. 2017 Apr;3(2-3):280-286. doi: 10.1016/j.euf.2016.07.002. Epub 2016 Jul 18. PMID: 28753776.

19: Lozano Martínez AJ, Moreno Cano R, Escobar Páramo S, Salguero Aguilar R, Gonzalez Billalabeitia E, García Fernández R, De La Fuente Muñoz I, Romero Borque A, Porras Martínez M, Lopez Soler F, Cardenas Cánovas E, Ortega Martín I. Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer. *Clin Transl Oncol*. 2017 Dec;19(12):1531-1536. doi: 10.1007/s12094-017-1699-x. Epub 2017 Jul 17. PMID: 28718070.

20: Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, Salvi S, Castellano D, Romanel A, Lolli C, Casadio V, Gurioli G, Amadori D, Font A, Vazquez-Estevez S, Gonzalez Del Alba A, Mellado B, Fernandez- Calvo O, Méndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez A, Santander C, Sáez MI, Puente J, Gasi Tandefelt D, Wingate A, Dearnaley D; PREMIERE Collaborators; Spanish Oncology Genitourinary Group, Demichelis F, De Giorgi U, Gonzalez-Billalabeitia E, Attard G. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. *Ann Oncol*. 2017 Jul 1;28(7):1508-1516. doi:

10.1093/annonc/mdx155. PMID: 28472366; PMCID: PMC5834043.

21: González Del Alba A, Arranz JÁ, Puente J, Méndez-Vidal MJ, Gallardo E, Grande E, Pérez-Valderrama B, González-Billalabeitia E, Lázaro-Quintela M, Pinto Á, Lainez N, Piulats JM, Esteban E, Maroto Rey JP, García JA, Suárez C. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment. *Crit Rev Oncol Hematol*. 2017 May;113:171-190. doi: 10.1016/j.critrevonc.2017.03.010. Epub 2017 Mar 14. PMID: 28427506.

22: Bellmunt J, Kerst JM, Vázquez F, Morales-Barrera R, Grande E, Medina A, González Graguera MB, Rubio G, Anido U, Fernández Calvo O, González-Billalabeitia E, Van den Eertwegh AJM, Pujol E, Perez-Gracia JL, González Larriba JL, Collado R, Los M, Maciá S, De Wit R; SOGUG and DUOS. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). *Ann Oncol*. 2017 Jul 1;28(7):1517-1522. doi: 10.1093/annonc/mdx186. PMID: 28419193.

23: Vila IK, Yao Y, Kim G, Xia W, Kim H, Kim SJ, Park MK, Hwang JP, González-Billalabeitia E, Hung MC, Song SJ, Song MS. A UBE2O-AMPK α 2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy. *Cancer Cell*. 2017 Feb 13;31(2):208-224. doi: 10.1016/j.ccell.2017.01.003. Epub 2017 Feb 2. PMID: 28162974; PMCID: PMC5463996.

24: Gonzalez-Billalabeitia E, Castellano D, Sobrevilla N, Guma J, Hervas D, Luengo MI, Aparicio J, Sanchez-Muñoz A, Mellado B, Saenz A, Valverde C, Fernandez A, Margeli M, Duran I, Fernandez S, Sastre J, Ros S, Maroto P, Manneh R, Cerezuela P, Carmona-Bayonas A, Ayala de la Peña F, Luis Aguilar J, Rivera S, García Del Muro X, Germà-Lluch JR; Spanish Germ Cell Cancer Group/Grupo Germinal (SGCCG). Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients. *J Natl Cancer Inst*. 2017 Jan 25;109(4). doi: 10.1093/jnci/djw265. PMID: 28122896.

25: Perez-Gracia JL, Sanmamed MF, Bosch A, Patiño-García A, Schalper KA, Segura V, Bellmunt J, Tabernero J, Sweeney CJ, Choueiri TK, Martín M, Fusco JP, Rodriguez-Ruiz ME, Calvo A, Prior C, Paz-Ares L, Pio R, Gonzalez-Billalabeitia E, Gonzalez Hernandez A, Páez D, Piulats JM, Gurrpide A, Andueza M, de Velasco G, Pazo R, Grande E, Nicolas P, Abad-Santos F, Garcia-Donas J, Castellano D, Pajares MJ, Suarez C, Colomer R, Montuenga LM, Melero I. Strategies to design clinical studies to identify predictive biomarkers in cancer research. *Cancer Treat Rev*. 2017 Feb;53:79-97. doi: 10.1016/j.ctrv.2016.12.005. Epub 2016 Dec 30. PMID: 28088073.

26: Aparicio J, Terrasa J, Durán I, Germà-Lluch JR, Gironés R, González-Billalabeitia E, Gumà J, Maroto P, Pinto A, García-Del-Muro X. SEOM clinical guidelines for the management of germ cell testicular cancer (2016). *Clin Transl Oncol*. 2016 Dec;18(12):1187-1196. doi: 10.1007/s12094-016-1566-1. Epub 2016 Nov 4. PMID: 27815687; PMCID: PMC5138244.

27: Suárez C, Puente J, Gallardo E, Méndez-Vidal MJ, Climent MA, León L, Olmos D, García del Muro X, González-Billalabeitia E, Grande E, Bellmunt J, Mellado B, Maroto P, González del Alba A. New advances in genitourinary cancer: evidence gathered in 2014. *Cancer Metastasis Rev*. 2015 Sep;34(3):443-64. doi: 10.1007/s10555-015-9577-x. PMID: 26227584.

28: Luengo-Gil G, González-Billalabeitia E, Chaves-Benito A, García Martínez E, García Garre E, Vicente V, Ayala de la Peña F. Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis. *Breast Cancer Res Treat*. 2015 Jun;151(3):577-87. doi: 10.1007/s10549-015-3421-4. Epub 2015 May 13. PMID: 25967462.

29: de la Morena Barrio P, Conesa MÁ, González-Billalabeitia E, Urrego E, García-Garre E, García-Martínez E, Poves MZ, Vicente V, de la Peña FA. Delayed recovery and increased severity of Paclitaxel-induced peripheral neuropathy in patients with diabetes. *J Natl Compr Canc Netw*. 2015 Apr;13(4):417-23. doi: 10.6004/jnccn.2015.0057. PMID: 25870378.

30: Urrego EG, Carmona-Bayonas A, González-Billalabeitia E, Ayala de la Peña F. Should anticoagulation therapy be withheld in patients with active cancer after 6 months of low-molecular weight heparin? *J Clin Oncol*. 2015 May 20;33(15):1713. doi: 10.1200/JCO.2014.60.6384. Epub 2015 Apr 13. PMID: 25870093.

31: García-Martínez E, Gil GL, Benito AC, González-Billalabeitia E, Conesa MA, García García T, García-Garre E, Vicente V, Ayala de la Peña F. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. *Breast Cancer Res*. 2014 Nov 29;16(6):488. doi: 10.1186/s13058-014-0488-5. PMID: 25432519; PMCID: PMC4303200.

32: González-Billalabeitia E, Seitzer N, Song SJ, Song MS, Patnaik A, Liu XS, Epping MT, Papa A, Hobbs RM, Chen M, Lunardi A, Ng C, Webster KA, Signoretti S, Loda M, Asara JM, Nardella C, Clohessy JG, Cantley LC, Pandolfi PP. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. *Cancer Discov*. 2014 Aug;4(8):896-904. doi: 10.1158/2159-8290.CD-13-0230. Epub 2014 May 27. PMID: 24866151; PMCID: PMC4125493.

- 33: Girones R, Aparicio J, Roure P, Germa-Lluch JR, García Del Muro X, Vazquez- Estevez S, Saenz A, Sastre J, Arranz Arija J, Gallardo E, Gonzalez-Billalabeitia E, Sanchez-Hernandez A, Terrasa J, Hernandez A, Santander C, Cillan E, Sagastibelza N, Almenar-Cubells D, Lopez Brea M, Maroto JP; Spanish Germ Cell Cancer Group (SGCCG). Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base. *Clin Transl Oncol*. 2014 Nov;16(11):959-65. doi: 10.1007/s12094-014-1179-5. Epub 2014 Apr 10. PMID: 24719184.
- 34: Lecumberri R, López Vivanco G, Font A, González Billalabeitia E, Gúrpide A, Gómez Codina J, Isla D, Galán A, Bover I, Domine M, Vicente V, Rosell R, Rocha E. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. *Thromb Res*. 2013;132(6):666-70. doi: 10.1016/j.thromres.2013.09.026. Epub 2013 Sep 27. PMID: 24491267.
- 35: Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez- Billalabeitia E, Egja A, Shaffer DR, Carver B, Liu XS, Taulli R, Kuo WP, Nardella C, Signoretti S, Cordon-Cardo C, Gerald WL, Pandolfi PP. Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. *Nat Genet*. 2013 Jul;45(7):739-746. doi: 10.1038/ng.2654. Epub 2013 Jun 2. PMID: 23727861; PMCID: PMC4036521.
- 36: Vicente Conesa MA, Garcia-Martinez E, Gonzalez Billalabeitia E, Chaves Benito A, Garcia Garcia T, Vicente Garcia V, Ayala de la Peña F. Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy. *Breast*. 2012 Aug;21(4):468-74. doi: 10.1016/j.breast.2011.11.002. Epub 2011 Nov 26. PMID: 22119767.
- 37: Carmona-Bayonas A, Gómez J, González-Billalabeitia E, Canteras M, Navarrete A, González ML, Vicente V, Ayala de la Peña F. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. *Br J Cancer*. 2011 Aug 23;105(5):612-7. doi: 10.1038/bjc.2011.284. Epub 2011 Aug 2. PMID: 21811253; PMCID: PMC3188929.
- 38: Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group. An international expanded- access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. *Eur J Cancer*. 2012 Feb;48(3):324-32. doi: 10.1016/j.ejca.2011.06.054. Epub 2011 Jul 29. PMID: 21803569.
- 39: González-Billalabeitia E, Calzas J, Castellano D, Mendiola C, Bezares S, Valentín V, Hornedo J, Ciruelo E, Cortés-Funes H. Long-term follow-up of an anthracycline-containing metronomic chemotherapy schedule in advanced breast cancer. *Breast J*. 2009 Sep-Oct;15(5):551-3. doi: 10.1111/j.1524-4741.2009.00783.x. Epub 2009 Aug 4. PMID: 19671111.
- 40: González-Billalabeitia E, Hitt R, Fernández J, Conde E, Martínez-Tello F, Enríquez de Salamanca R, Cortés-Funes H. Pre-treatment serum lactate dehydrogenase level is an important prognostic factor in high-grade extremity osteosarcoma. *Clin Transl Oncol*. 2009 Jul;11(7):479-83. doi: 10.1007/s12094-009-0388-9. PMID: 19574207.
- 41: Zafra M, Ayala F, Gonzalez-Billalabeitia E, Vicente E, Gonzalez-Cabezas P, García T, Macías JA, Vicente V. Impact of whole-body 18F-FDG PET on diagnostic and therapeutic management of Medical Oncology patients. *Eur J Cancer*. 2008 Aug;44(12):1678-83. doi: 10.1016/j.ejca.2008.05.021. Epub 2008 Jul 7. PMID: 18614352.
- 42: Gonzalez-Billalabeitia E, Quintela-Fandino M, Alemany I, López-Alonso G, Ruiz-Ollero A, Martínez-Tello F, Hitt R. Coexistence of two rare sarcomas: primary leiomyosarcoma of bone and epithelioid hemangioendothelioma of the liver. *Sarcoma*. 2008;2008:416085. doi: 10.1155/2008/416085. PMID: 18382610; PMCID: PMC2276596.
- 43: Carmona-Bayonas A, Soler IO, Gómez FI, Billalabeitia EG, Saura HP, Tafalla MS, Díaz MP. Tailored hormonal therapy in secretory adrenocortical cancer. *Ann Oncol*. 2007 Jul;18(7):1281. doi: 10.1093/annonc/mdm273. PMID: 17675396.
- 44: del Mar Osma M, Gonzalez-Billalabeitia E, Ortuño FJ, Jerez A, Ayala F, Vicente V. Transient massive peripheral blood blastosis in patient with renal clear-cell carcinoma after treatment with high-dose recombinant interleukin-2. *Lancet Oncol*. 2007 Mar;8(3):275-6. doi: 10.1016/S1470-2045(07)70079-7. PMID: 17329199.
- 45: Jimeno A, García-Velasco A, del Val O, González-Billalabeitia E, Hernando S, Hernández R, Sánchez-Muñoz A, López-Martín A, Durán I, Robles L, Cortés-Funes H, Paz-Ares L. Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. *Cancer*. 2004 Jun 1;100(11):2462-9. doi: 10.1002/cncr.20275. PMID: 15160353.
- 46: Sánchez-Muñoz A, López-Medrano F, Artilles Valle V, Jimeno Largo A, González- Billalabeitia E. Isquemia intestinal aguda extensa en el seno de carcinoma de colon con recidiva local [Extensive acute intestinal ischemia in a patient with colon carcinoma with local recurrence]. *Rev Clin Esp*. 2003

Oct;203(10):489-90. Spanish. doi: 10.1016/s0014-2565(03)71335-6. PMID: 14563243.

Projects

Memberships

Other Relevant Information